Generated by AI
Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.
Website500 North Beacon Street
Watertown, MA, 02472
United States
The latest articles about KYMR.
Kymera Therapeutics has delivered very strong share-price gains in recent years, and that kind of move naturally raises the question of whether the current valuation is still grounded in its underlying book value. With the stock now in a very different place than it was a few years ago, investors are asking how much of the story is already reflected on the balance sheet. Over the past 3 years the share price has climbed by more than 7x. That puts real weight on the question of how its...
Summary of Nov 3's posts. Generated by AI.
Summary of Dec 9's posts. Generated by AI.
Summary of Dec 11's posts. Generated by AI.
Summary of Jun 27's posts. Generated by AI.
Investors talking about KYMR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.